Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Synaptogenix Announces FDA IND Authorization for Bryostatin-1 Trial in Multiple Sclerosis
Details : Bryostatin-1 is a small molecule that works by activating protein kinase C enzymes. Currently, it is being evaluated as a potential treatment for multiple sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2024
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Synaptogenix
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of Bryostatin in Patients With MS
Details : Bryostatin 1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2024
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Synaptogenix
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bryostatin-1, a small molecule that works by activating protein kinase C, which is investigated for the treatment of amyotrophic lateral sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 07, 2023
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Synaptogenix
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to conduct a phase 1 trial of Bryostatin-1, a small molecule that works by activating protein kinase C, in multiple sclerosis (MS).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 19, 2023
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Synaptogenix
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 16, 2022
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Katalyst Securities
Deal Size : $15.0 million
Deal Type : Private Placement
Synaptogenix Announces $15 Million Private Placement with Existing Investors
Details : Bryostatin-1 is a powerful protein kinase C (PKC) agonist, activating PKC isozymes at nanomolar concentrations. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndro...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 18, 2022
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Katalyst Securities
Deal Size : $15.0 million
Deal Type : Private Placement
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data
Details : Bryostatin 1 is a natural product derived from a marine microorganism called Bugula neritina, for patients suffering from advanced and moderately severe Alzheimer's disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 26, 2022
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bryostatin-1 is a small molecule that works by activating protein kinase C (PKC) in the brain. PKC is an enzyme that plays an important role in maintaining the health of synapses, which are the connections between neurons (nerve cells).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 20, 2022
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Synaptogenix to Present at the Cell Symposium
Details : Preclinical studies have also demonstrated Bryostatin-1 regenerative mechanisms of action for the rare disease, as a treatment for Fragile X syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial
Details : Bryostatin-1 caused highly significant cognitive enhancement for pre-specified patients who received Bryostatin-1 in absence of Namenda in our two previous, consolidated 3-month pilot trials, while the Placebo-treated patients showed no significant benef...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 19, 2022
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
